Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2018 Oct 8:13:3065-3076.
doi: 10.2147/COPD.S170747. eCollection 2018.

Eosinophil counts in first COPD hospitalizations: a 1-year cost analysis in Quebec, Canada

Thomas G Poder  1   2   3 , Nathalie Carrier  1 , Maryse Bélanger  1   4 , Simon Couillard  1   4 , Josiane Courteau  1 , Pierre Larivée  1   4 , Alain Vanasse  1   3
Affiliations
Observational Study

Eosinophil counts in first COPD hospitalizations: a 1-year cost analysis in Quebec, Canada

Thomas G Poder et al. Int J Chron Obstruct Pulmon Dis. .

Abstract

Background: Exacerbations explain much of the cost of COPD. Higher blood eosinophil cell counts at admission for acute exacerbation of COPD increase the risk of subsequent exacerbations and hospitalizations. However, there is no literature on the economic burden of patients with this inflammatory profile. The objective of this study is to assess the cost of health-care service utilization according to different counts of blood eosinophils.

Methods: The observational retrospective cohort included all first hospitalizations for COPD exacerbation between April 2006 and March 2013. The eosinophilic group was defined by blood eosinophil counts on admission ≥200 cells/µL and/or ≥2% of the total white blood cell count. Study outcomes were: total costs (2016 Canadian dollars) (index hospitalization and 1-year follow-up), total index hospitalization costs, total 1-year costs (all-cause readmissions, ambulatory and emergency service use), and 1-year COPD-related costs (only cost for COPD after initial discharge). Sensitivity analyses were conducted to evaluate the impact of different eosinophil cut-offs on outcomes.

Results: In total, 479 patients were included, 173 in the eosinophilic group (92 in the higher cut-off). The average total cost was $18,263 ($6,706 for the index hospitalization), without significant difference between groups (P=0.3). The average 1-year COPD-related cost was higher in the eosinophilic group ($3,667 vs $2,472, P=0.006), with an adjusted mean difference of $1,416. Analysis of data using the higher cut-off of ≥400 cells or ≥3% was associated with a slightly larger difference in 1-year COPD-related costs between groups ($4,060 vs $2,629, P=0.003), with an adjusted mean difference of $1,640.

Conclusion: A higher blood eosinophil cell count at admission for a first hospitalization is associated with an increase in total 1-year COPD-related costs.

Keywords: Canada; Quebec; chronic obstructive pulmonary disease; cohort study; exacerbations; health-care utilization.

PubMed Disclaimer

Conflict of interest statement

Disclosure AV and TGP report grants from AstraZeneca Canada Inc, during the conduct of the study; PL reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, and Novartis, grants from Sanofi, and personal fees from Merck, outside the submitted work. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Flowchart of patient selection process. Note: *Main diagnosis ICD-10: J40–J44. Abbreviations: AECOPD, acute exacerbation of COPD; CBC, complete blood count; CHUS, Centre Hospitalier Universitaire de Sherbrooke; H, hospitalization; PFT, pulmonary function test.
Figure 2
Figure 2
Cost distribution according to eosinophilia group (≥200 cells or ≥2%). Note: ^P<0.01.
See this image and copyright information in PMC

References

    1. GBD 2015 Chronic Respiratory Disease Collaborators Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691–706. - PMC - PubMed
    1. Canadian Institute for Health Information . All-Cause Readmission to Acute Care and Return to the Emergency Department. Ottawa, Ont.: CIHI; 2012.
    1. Wier LM, Elixhauser A, Pfuntner A, Au DH. Overview of Hospitalizations among Patients with COPD, 2008. HCUP Statistical Brief #106. Rockville, MD: Agency for Healthcare Research and Quality; Feb, 2011. [Accessed September 10, 2018]. Available from: http://www.hcup-us.ahrq.gov/reports/stat-briefs/sb106.pdf. - PubMed
    1. Mannino DM, Braman S. The epidemiology and economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2007;4(7):502–506. - PubMed
    1. Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest. 2000;118(5):1278–1285. - PubMed

Publication types

MeSH terms